PPI-383

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NamePPI-383
Drug Alias NamePPI-383
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomMauritius
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPresidio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPresidio Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A